Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-10-21
Recursion Pharmaceuticals, Inc.
Recursion is a clinical-stage biotech that uses proprietary biological data, automated labs, and AI-driven software to discover and develop internal and partnered medicines.
ai automation biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Clinical Proof, Not Compute, Sets the Outcome
Fresh capital and partner validation have improved the setup, but the five-year case still rests on whether platform output becomes approval-shaped assets and repeatable partner economics. The upside is material if one owned program and several external programs convert before dilution becomes the dominant narrative again.

Analysis

Thesis
Recursion has bought enough time and capital to try a real business-model upgrade: if it can turn its data-and-automation engine into one approval-shaped internal asset plus repeatable partner milestones and royalties, the stock can re-rate from speculative tool story to validated platform biotech over the next five years.
Last Economy Alignment
Cheaper cognition helps Recursion because it owns proprietary biology data, automated lab throughput, and licensing/royalty capture rather than a seat-based software layer; the main limiter is FDA and clinical proof, not AI price compression.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
3.6x (from 5 most recent analyses)
Reasoning
The upside is not selling more discovery work; it is proving that the engine can repeatedly create assets and partner economics that deserve a higher-quality biotech multiple. Fresh capital and the Sanofi step-up reduce near-term financing pressure, so the next value jump can come from REC-4881, REC-1245, and more milestone conversion. I see a plausible 2-5x outcome, but not a clean hypergrowth case yet because FDA and clinical gates still dominate.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The core risk is not that AI becomes cheaper; it is that Recursion fails to capture the value of its AI-and-lab engine before regulators, biology, and partner bargaining power do. The lead bottleneck is FDA permissioning on REC-4881, followed by broader proof that the platform can generate repeatable clinical and milestone outcomes. Fresh financing helps, but it does not remove the need for approval-shaped evidence.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.42
They own a biology data factory, automated labs, and the workflow that turns experiments into drug ideas, so cheaper AI makes their engine more useful instead of replacing it. The risk is simple: if those insights do not survive FDA and clinical testing, partners keep the durable value and shareholders just fund the learning curve.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.32
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case